Dr. Shaper Mirza holds a BSc (Hon) degree from University of Karachi and a doctorate from The University of Alabama at Birmingham (UAB). Her PhD studies involved understanding mechanisms of nasal colonisation by a Gram-positive pathogen Streptococcus pneumoniae. More specifically the work was focused on understanding the interaction of a human mucosal protein lactoferrin with pneumococcal surface proteins and its downstream effects on colonisation by Streptococcus pneumoniae. Dr. Mirza received several awards and honours during her PhD which included a student travel grant award for Gordon Conference on Structure and Functions of Lactoferrin, held in Hawaii 2005;  Gail Castle award for best poster presentation as PhD student and Gail Castel Award for best post-doctoral presentation.

Prior to joining LUMS in 2015, Dr. Mirza served as an Assistant Professor since 2008, at The University of Texas – Houston Health Science Center in the Division of Epidemiology Human Genetics and Environmental Health. While working at the Brownsville (Texas) regional campus Dr. Mirza started elucidating the relationship between immune impairments in type-2 diabetes and their impact on pneumococcal infections in individuals with type-2 diabetes. Her studies are the first to demonstrate impairments in immune mechanisms in type-2 diabetes that are critical for protection against pneumococcal infections. 

Dr. Mirza joined LUMS as an Associate Professor in the Department of Biology at Syed Babar Ali School of Science and Engineering. Dr. Mirza’s specialised areas of teaching at LUMS include immunology and bacterial pathogenesis, where she continues to develop her studies on association of immune impairments in diabetes with pneumococcal infections. While teaching at LUMS, Dr. Mirza has also developed a lab as part of her programme, which is currently investigating the role of hyperglycemia, characteristic of type-2 diabetes in impairment in immune functions of neutrophils and CD4+T cells. Information derived from these studies will be valuable in developing more targeted vaccines for prevention and control of invasive pneumococcal disease in this high-risk population. Given the global increase in the incidence of type-2 diabetes, the work is of significant public health relevance.

Dr. Mirza is a recognised researcher in the areas of molecular pathogenesis. She has authored several papers in high impact factor journals and serves as an editor for two journals.

Title Publication Author Year
Author Correction: An evaluation of lipid profile and pro-inflammatory cytokines as determinants of cardiovascular disease in those with diabetes: a study on a Mexican American cohort (Scientific Reports, (2021), 11, 1, (2435), 10.1038/s41598-021-81730-6) Scientific Reports 2021
An evaluation of lipid profile and pro-inflammatory cytokines as determinants of cardiovascular disease in those with diabetes: a study on a Mexican American cohort Scientific Reports 2021
Host biomarkers for monitoring therapeutic response in extrapulmonary tuberculosis Cytokine 2021
Trends in antimicrobial resistance amongst pathogens isolated from blood and cerebrospinal fluid cultures in Pakistan (2011-2015): A retrospective cross-sectional study PLoS ONE 2021
Green synthesis of zinc oxide nanoparticles by Neem extract as multi-facet therapeutic agents Journal of Drug Delivery Science and Technology 2020
An engineered microvirin variant with identical structural domains potently inhibits human immunodeficiency virus and hepatitis C virus cellular entry Viruses 2020
PspA facilitates evasion of pneumococci from bactericidal activity of neutrophil extracellular traps (NETs) Microbial Pathogenesis 2019
Evolution of efficacious pangenotypic hepatitis C virus therapies Medicinal Research Reviews 2019
Estimation of hepatitis C prevalence in the Punjab province of Pakistan: A retrospective study on general population PLoS ONE 2019
The effects of differences in pspA alleles and capsular types on the resistance of Streptococcus pneumoniae to killing by apolactoferrin Microbial Pathogenesis 2016
Combined effects of lactoferrin and lysozyme on Streptococcus pneumoniae killing Microbial Pathogenesis 2015
Meeting Physical Activity Guidelines is Associated with Lower Allostatic Load and Inflammation in Mexican Americans Journal of Immigrant and Minority Health 2015
Infection and cellular defense dynamics in a novel 17??-estradiol murine model of chronic human group B streptococcus genital tract colonization reveal a role for hemolysin in persistence and neutrophil accumulation Journal of Immunology 2014
Impaired CD4+ and T-helper 17 cell memory response to Streptococcus pneumoniae is associated with elevated glucose and percent glycated hemoglobin A1c in Mexican Americans with type 2 diabetes mellitus Translational Research 2014
Novel recombinant human lactoferrin: Differential activation of oxidative stress related gene expression Journal of Biotechnology 2013
Modified opsonization, phagocytosis, and killing assays to measure potentially protective antibodies against pneumococcal surface protein A Clinical and Vaccine Immunology 2013
Pneumococcal surface protein A inhibits complement deposition on the pneumococcal surface by competing with the binding of C-reactive protein to cell-surface phosphocholine Journal of Immunology 2012
PNPLA3 polymorphisms and liver aminotransferase levels in a Mexican American population Clinical and Investigative Medicine 2012
Impaired function of antibodies to pneumococcal surface protein A but Not to capsular polysaccharide in Mexican American adults with type 2 diabetes mellitus Clinical and Vaccine Immunology 2012
Type 2-diabetes is associated with elevated levels of TNF-alpha, IL-6 and adiponectin and low levels of leptin in a population of Mexican Americans: A cross-sectional study Cytokine 2012
Adiponectin/leptin ratio and metabolic syndrome in a mexican american population Clinical and Investigative Medicine 2011
Serine protease PrtA from Streptococcus pneumoniae plays a role in the killing of S. pneumoniae by apolactoferrin Infection and Immunity 2011
Structure of a Complex of Human Lactoferrin N-lobe with Pneumococcal Surface Protein A Provides Insight into Microbial Defense Mechanism Journal of Molecular Biology 2007
Capsule does not block antibody binding to PspA, a surface virulence protein of Streptococcus pneumoniae Microbial Pathogenesis 2006
Erratum: PspA protects Streptococcus pneumoniae from killing by apolactoferrin, and antibody to PspA enhances killing of pneumococci by apolactoferrin (Infection and Immunity (2004) 72, 9 (5031-5040)) Infection and Immunity 2004